Institutional members access full text with Ovid®

Share this article on:

Phase I Study of Fixed Dose Gemcitabine Plus Epirubicin in Patients With Advanced Solid Malignancies

Mahadevan, Daruka MD, PhD*; Dreisbach, Luke MD; Kristedja, Timothy MD*; Williams, Debbie RN*; Obregon, Yrma*; Kurtin, Sandy NP*; Von Hoff, Daniel D. MD

American Journal of Clinical Oncology: December 2009 - Volume 32 - Issue 6 - p 607-611
doi: 10.1097/COC.0b013e31819cc9ed
Original Article: Experimental Therapeutics

Objectives: A Phase I study was initiated to investigate fixed dose rate gemcitabine (GEM) combined with epirubicin (EPI) given weekly or every other week, since, GEM given as a standard 30 minute infusion has modest activity. The study was designed based on the hypothesis that prolonged exposure (over 90 minutes) may improve response rates and combination with epirubicin (EPI) is synergistic.

Methods: Eligible patients had measurable refractory solid malignancies with adequate bone marrow, renal, and liver functions. Patients received GEM 800, 1000, 1250 mg/m2 over 90 minutes followed by EPI 10 or 15 mg/m2 as a 30 minutes infusion on days 1, 8, and 15 or days 1 and 15 of a 28 day cycle.

Results: Twenty-eight patients were enrolled and 24 are evaluable for overall toxicities and response rate. Toxicities include neutropenia (Gr 3 of Gr 4, 9 pts), thrombocytopenia (Gr 3 of Gr 4, 3 pts), fatigue (Gr 3 of Gr 4, 4 pts), and myalgia (Gr 3 of Gr 4, 1 pt). Dose limiting toxicity was grade 4 neutropenia. Seven patients experienced stable disease for >16 weeks and 3 patients with pancreatic cancer had partial responses.

Conclusions: The maximum tolerated dose is GEM 800 mg/m2/EPI 10 mg/m2 days 1, 8, 15 or GEM 1000 mg/m2/EPI 15 mg/m2 days 1, 15 given every 4 weeks. Further studies are warranted with targeted therapies to define the efficacy of this doublet.

From the *Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson, Arizona; †Desert Hematology/Oncology, Rancho Mirage, California; and ‡Translational Genomics Research Institute, Phoenix, Arizona.

Reprints: Daruka Mahadevan, MD, PhD, 1515 N Campbell Ave Tucson, AZ 85724. E-mail:

© 2009 Lippincott Williams & Wilkins, Inc.